As Dr. Balon implies, our procedures differed from those of Dr. Gelfin and colleagues in a number of ways. These differences may have contributed to an apparent inconsistency of findings. First, we administered SSRI and placebo concurrently to different groups (by means of a double-blind procedure), rather than sequentially to the same subjects. Second, we mainly used psychometric measures developed for normal rather than clinical samples, which may have reduced our susceptibility to floor effects. Third, we also observed changes in objectively coded interpersonal behavior. Fourth, we measured plasma SSRI levels, which afforded some control for compliance or idiosyncratic malabsorption of the drug. Fifth, we tested a larger number of subjects, which may have boosted our statistical power to detect an effect.